Minnesota startup Respicardia secured $6 million in debt financing to advance clinical trial work for a unique implantable device. As the Minneapolis/St. Paul Business Journal reports, the treatment is targeted toward heart failure patients who also experience central sleep apnea, where patients stop breathing briefly through the night. Ares Capital supplied the funding. Story (sub. req.)